Cinnamamides, Novel Liver X Receptor Antagonists that Inhibit Ligand-Induced Lipogenesis and Fatty Liver
Open Access
- 1 December 2015
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 355 (3) , 362-369
Abstract
Liver X receptor (LXR) is a member of the nuclear receptor superfamily, and it regulates various biologic processes, including de novo lipogenesis, cholesterol metabolism, and inflammation. Selective inhibition of LXR may aid the treatment of nonalcoholic fatty liver diseases. In the present study, we evaluated the effects of three cinnamamide derivatives on ligand-induced LXRα activation and explored whether these derivatives could attenuate steatosis in mice. N-(4-trifluoromethylphenyl) 3,4-dimethoxycinnamamide (TFCA) decreased the luciferase activity in LXRE-tk-Luc-transfected cells and also suppressed ligand-induced lipid accumulation and expression of the lipogenic genes in murine hepatocytes. Furthermore, it significantly attenuated hepatic neutral lipid accumulation in a ligand-induced fatty liver mouse system. Modeling study indicated that TFCA inhibited activation of the LXRα ligand-binding domain by hydrogen bonding to Arg305 in the H5 region of that domain. It regulated the transcriptional control exerted by LXRα by influencing coregulator exchange; this process involves dissociation of the thyroid hormone receptor–associated proteins (TRAP)/DRIP coactivator and recruitment of the nuclear receptor corepressor. These results show that TFCA has the potential to attenuate ligand-induced lipogenesis and fatty liver by selectively inhibiting LXRα in the liver.Keywords
This publication has 35 references indexed in Scilit:
- Single Oral Dose Toxicity Study of Prebrewed Armeniacae Semen in RatsToxicological Research, 2013
- Liver X receptor biology and pharmacology: new pathways, challenges and opportunitiesTrends in Pharmacological Sciences, 2012
- Surflex-Dock: Docking benchmarks and real-world applicationJournal of Computer-Aided Molecular Design, 2012
- Inflammation Is Necessary for Long-Term but Not Short-Term High-Fat Diet–Induced Insulin ResistanceDiabetes, 2011
- Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liverJournal of Lipid Research, 2011
- Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levelsBritish Journal of Pharmacology, 2010
- Synthesis of riccardin C and its seven analogues. Part 1: The role of their phenolic hydroxy groups as LXRα agonistsBioorganic & Medicinal Chemistry Letters, 2009
- Principles for modulation of the nuclear receptor superfamilyNature Reviews Drug Discovery, 2004
- Diminished Hepatic Response to Fasting/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1cJournal of Biological Chemistry, 2002
- Determinants of CoRNR-Dependent Repression Complex Assembly on Nuclear Hormone ReceptorsMolecular and Cellular Biology, 2001